Last reviewed · How we verify
EP-2101
At a glance
| Generic name | EP-2101 |
|---|---|
| Sponsor | Epimmune |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure (PHASE3)
- Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer (PHASE2)
- An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer (PHASE1)
- An Open Label Study of a Peptide Vaccine in Patients With Stage III Colon Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EP-2101 CI brief — competitive landscape report
- EP-2101 updates RSS · CI watch RSS
- Epimmune portfolio CI